Cynvenio Biosystems Scores Insurance Reimbursement Win

Westlake Village-based Cynvenio Biosystems said this week that it has scored a big win for its genomic testing products, with the company's ClearID Breast Cancer test now reimburseable under most health insurance plans. Cynvenio said its cancer therapy blood test is being accepted by Aetna, UnitedHealth Group, Cigna, Assurant, Blue Cross/Blue Shield, Humana, Kaiser Permanente and others. Cynvenio's test uses a blood test and DNA sequencing to monitor patient response to cancer treatment, and is an alternative to more invasive tissue biopsies. Cynvenio is led by Andre de Fusco.